Anthem Biosciences Limited · NSE:ANTHEM

Anthem Biosciences — Q4 FY2026 Earnings Presentation

13 slides from Anthem Biosciences's earnings presentation, May 19, 2026

  1. Slide 1: Exchange filing cover letter for earnings presentation

    Date: May 19, 2026 To, BSE Limited, National Stock Exchange of India Limited 20th Floor, P.J. Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai - 400001. Mumbai – 400 051 BSE Scrip Code: 544449 NSE Scrip Symbol: ANTHEM Subject: Earnings Call Presentation of

  2. Slide 2: Anthem Biosciences Limited Investor Presentation

    Anthem Biosciences Limited Investor Presentation May 19, 2026

  3. Slide 3: Safe Harbour

    Safe Harbour Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "

  4. Slide 4: Message from Chairman, MD and CEO

    Message from Chairman, MD and CEO “We ended the financial year 2025–26 on a strong note, with our highest revenue quarter ever in Q4FY26. We delivered a Revenue growth of 26% YoY for the quarter and 15% YoY for the financial year 2025-26. Anthem’s commitment to prudent cost management and focus on l

  5. Slide 5: Consolidated Profit & Loss Statement: Q4FY26 vs Q4FY25 vs Q3FY26 Performance

    Consolidated Profit & Loss Statement: Q4FY26 vs Q4FY25 vs Q3FY26 Performance Particulars (₹ Mn) Q4FY26 Q4FY25 YoY Q3FY26 QoQ FY25 Revenue from Operations 6,109 4,832 26.4% 4,232 44.4% 18,446 CRDMO 5,128 3,923 30.7% 3,332 53.9% 15,061 Specialty Ingredients 981 909 7.9% 899 9.1% 3,385 Other Income 512

  6. Slide 6: Q4FY26 Consolidated Financial Highlights

    Q4FY26 Consolidated Financial Highlights Revenues (₹ Mn) EBITDA1 (₹ Mn) and EBITDA Margins (%age) PAT (₹ Mn) and PAT Margins (%age) 6,109 4,832 42.1% 48.1% 28.7% 16.6% 3,184 2,092 1,898 826 Q4FY25 Q4FY26 Q4FY25 Q4FY26 Q4FY25 Q4FY26 PBT after exceptional items2 (₹ Mn) Net Cash (₹ Mn) Specialty and PB

  7. Slide 7: Margin profile continues to remain strong in the highest revenue quarter ever

    Margin profile continues to remain strong in the highest revenue quarter ever in Q4FY26 ₹6,109 Mn 48.1% 28.7% Strong Business Q4FY26 Revenues Q4FY26 EBITDA Margin Q4FY26 PAT Margin Performance 2,282 / 1,117 425KL 142KL Robust Technology # Employees / Scientific Staff Custom Synthesis Capacity Fermen

  8. Slide 8: Consolidated Profit & Loss Statement: FY26 vs FY25 Performance

    Consolidated Profit & Loss Statement: FY26 vs FY25 Performance Particulars (₹ Mn) FY26 FY25 YoY Revenue from Operations 21,243 18,446 15.2% CRDMO 17,727 15,061 17.7% Specialty Ingredients 3,516 3,385 3.9% Other Income 1,558 857 81.8% Total Revenues 22,801 19,303 18.1% Cost of materials consumed and

  9. Slide 9: FY26 Consolidated Financial Highlights

    FY26 Consolidated Financial Highlights Revenues (₹ Mn) EBITDA1 (₹ Mn) and EBITDA Margins (%age) PAT (₹ Mn) and PAT Margins (%age) 21,243 18,446 43.4% 39.2% 23.4% 26.0% 40.0% 30.0% 20.0% 10.0% 0.0% 9,896 5,918 7,566 4,513 FY25 FY26 FY25 FY26 FY25 FY26 PBT after exceptional items2 (₹ Mn) Net Cash (₹ M

  10. Slide 10: FY26 performance continues to be robust

    FY26 performance continues to be robust: 15%+ Revenue Growth & 30%+ EBITDA & PAT Growth ₹21,243 Mn 43.4% 26.0% Strong Business FY26 Revenues FY26 EBITDA Margin FY26 PAT Margin Performance 60.8% 14 14.5% Platforms across Commercial Molecules D&M FY26 Commercial Molecules discovery to FY26 Contributio

  11. Slide 11: Financial Highlights: FY26 and Q4FY26

    Financial Highlights: FY26 and Q4FY26 Full Year Performance:  Consolidated Revenue from Operations was ₹21,243 Mn for the year  CRDMO business delivered ₹17,727 Mn revenues  Specialty Ingredients delivered ₹3,516 Mn revenues  EBITDA was ₹9,896 Mn, with EBITDA margins at 43.4%  PAT (Profit After

  12. Slide 12: Financial Highlights: FY26 and Q4FY26

    Financial Highlights: FY26 and Q4FY26  Exceptional Items:  On November 21, 2025, the Government of India notified four new Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code

  13. Slide 13: Thank You

    Thank You Anthem Biosciences Limited NeoAnthem Lifesciences Private Limited Unit I: No.49, F1 &F2, Canara Bank Road, Unit III: 313-P,314-P, 318-P, Harohalli Bommasandra Industrial Area Phase 1, Industrial Area, Phase II, Bommasandra, Bangalore, 560 099, India Kanakapura Taluk, Ramnagar District, Har

Anthem Biosciences — Q4 FY2026 Earnings Presentation on 6ix